Karolinska Development divests shares in portfolio company OssDsign
Karolinska Development has been a long-term owner of OssDsign and was involved in the listing of the company on Nasdaq First North Growth Market in Stockholm in 2019.
Advertisement
'We have been on a long journey with OssDsign and supported the company through several important stages. In recent periods, OssDsign has demonstrated strong value development, which is also reflected in the share price. We have decided to realize the profit in Karolinska Development's holdings and prioritize other investments where we see greater value creation potential, and a higher possible return on investment. The sale strengthens our financial position and increases our capacity to invest in other holdings,' says Viktor Drvota, CEO Karolinska Development.
Following the divestment, Karolinska Development has no direct ownership in OssDsign, but an indirect ownership via KCIF Co-Investment Fund remains.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: [email protected]
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: [email protected]
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
Attachment
PM KD OssDsign avyttring aktier juni 2025 ENG KLAR
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
42 minutes ago
- CNBC
Chinese car brands are rapidly making inroads in Europe's EV utopia
OSLO, Norway — China is hoovering up market share in electric vehicle-friendly Norway, posing significant competition to Elon Musk's Tesla and other Western auto giants. From the first delivery of an MG car to the wealthy Nordic country in January 2020, Chinese EV brands have gone on to capture a combined market share of roughly 10%, driven by Beijing's competitive pricing and advanced technology. The explosive growth is particularly notable, given Norway's decision not to impose tariffs on Chinese EV imports — as well as its reputation as the world's most EV-friendly country. Norway's tariff policy sets it apart from both the U.S. and European Union, which have both slapped duties on Chinese-made EVs to protect traditionally dominant American and European brands. Norway, which is not a member of the EU, has said previously that it is neither relevant nor desirable to slap tariffs on Chinese EVs. A Norwegian finance ministry spokesperson was not immediately available to comment when contacted by CNBC. Christina Bu, secretary general of the Norwegian EV Association (NEVA), which represents electric car owners in the country, said that at least 20 different Chinese EV models are currently available in the Norwegian market. She noted that the view on Chinese EVs among prospective Norwegian buyers has "changed a lot" in recent years. "They see that [they are] good cars, technologically they are good and also quite competitive when it comes to price. So, it's a really, really competitive EV market in Norway. We are at close to 94% market share in the first six months this year," Bu told CNBC during an interview at NEVA's office in Oslo. Chinese EV manufacturers such as BYD, XPeng and MG were among the top 20-selling companies in Norway's new car market last month, according to data from the Norwegian Road Federation (OFV). Sweden's Volvo and Polestar were also on the list. China's Geely Holding Group holds a significant stake in both car manufacturers. Tesla, meanwhile, remains the dominant player in Norway. The U.S. EV maker was by far the best-selling brand in Norway in June, with sales boosted by demand for the firm's revamped Model Y sports utility vehicle. Felipe Munoz, global analyst at research firm JATO Dynamics, said his own definition of a Chinese brand includes all businesses that make cars that are fully designed, conceived and produced in China — such as MG, which is part of China's SAIC Motor. The likes of Volvo, Polestar and Lotus, however, would be excluded, even if they are fully or partly owned by a Chinese original equipment manufacturer. Based on this definition, Munoz said Norway is the European country where Chinese car brands have accumulated their largest market share at 10.04% between January and June 2025. "Due to its regulation, culture, and size, Norway is Europe's laboratory for EVs. It means that it is somehow the entry point for all the unknown brands willing to sell EVs in the rest of the continent," Munoz told CNBC by email. "It is easier to start there than anywhere in Europe and does not require big investments as in Europe's big 5 markets. Besides, Norway does not have its own auto industry, meaning that it is easier for an outsider to gain traction without hurting the interests of anyone." Rico Luman, senior sector economist for transport and logistics at Dutch bank ING, said surveys have shown that European drivers enjoy driving Chinese EVs. "So, that is a real challenge for Tesla going forward, to compete with those new brands which are building up their presence in Europe," Luman told CNBC's "Squawk Box Europe" on Friday. Asked whether Europe appears to be losing its EV battle with China, ING's Luman said "Europe is catching up a bit," but noted that China remains far ahead. "There is also some backtracking in the U.S. so the EU and Europe in general is somewhere in the middle. We really need more new models and more affordable models to convince the middle-class driver to make the shift – and we're not there yet," Luman said.
Yahoo
2 days ago
- Yahoo
Nordic Cold Chain launches cold chain packaging for GLP-1 drugs
Temperature-controlled packaging solutions provider Nordic Cold Chain Solutions has introduced what it claims to be the first cold chain packaging solution tailored for transporting glucagon-like peptide-1 (GLP-1) medications. The company noted that the GLP-1 drugs necessitate consistent temperature regulation during transit to preserve their therapeutic effectiveness and adhere to regulatory standards. The solution, dubbed the Nordic Express Pack, is designed specifically for this purpose, providing a dependable and user-friendly packing option to assist speciality pharmacies and healthcare distributors in managing increasing demand. Featuring a compact, space-efficient design, the Nordic Express Pack minimises storage requirements and enables swift operational expansion as demand rises. The packaging is engineered to enhance efficiency for both incoming and outgoing freight, reducing shipping costs while meeting stringent quality standards. Incorporated temperature indicators offer visual confirmation of any temperature deviations through colour changes. The solution has undergone testing in International Safe Transit Association-certified laboratories, demonstrating its performance in extreme seasonal conditions. Nordic Cold Chain Solutions CCO Keith Baechle said: 'Nordic has always been built on a customer-first foundation, focused on truly understanding our partners' needs and the demands of the marketplace. 'We built the Nordic Express Pack to solve the real-world challenges of GLP-1 shipping. While there are plenty of generic cold chain mailers available, none have been specifically designed and tested for shipping GLP-1 therapies. 'With this launch, we're delivering a faster-to-pack, easier-to-store solution that protects these critical medications without driving up costs." Nordic Cold Chain offers a range of products and services to clients in the cold chain industry. In October 2024, the company successfully acquired Minus Works, a US-based manufacturing company focused on developing sustainable cold chain packaging and shipping products. "Nordic Cold Chain launches cold chain packaging for GLP-1 drugs" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Yahoo
Arjo AB (FRA:A39) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst Global Challenges
Organic Net Sales Growth: 3.0% for Q2 2025. Gross Margin: 43.4%, slightly down from 43.6% last year. Adjusted EBITDA: SEK475 million, down from SEK496 million in Q2 2024. Operational Cash Flow: SEK205 million, with a cash conversion of 47%. Net Debt to Adjusted EBITDA: SEK2.3 million, slightly down from SEK2.4 million in Q2 2024. Equity Ratio: 48.7%, down from 51.2% in Q1 2025. North America Business Growth: Double-digit organic growth, with the US as the main growth engine. Western Europe Sales Decline: -2.4% due to difficult comparisons and weaker UK market. Rest of the World Organic Net Sales Growth: 0.5%, with India showing 40% growth. Restructuring Costs: SEK34 million related to changes in China and global sales structure. Cash Flow from Investing Activities: SEK171 million, up from SEK112 million last year. Dividend Payout: SEK259 million to shareholders. Warning! GuruFocus has detected 7 Warning Sign with GJNSY. Release Date: July 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Arjo AB (FRA:A39) reported a 3.0% organic net sales growth in Q2 2025, supported by a significantly stronger order intake. The North America business, particularly the US, showed double-digit organic growth, driven by strong demand across product categories. Several European countries, including France, Germany, and Italy, experienced good demand and strong organic net sales growth. The company has been successful in implementing cost efficiency measures, which are beginning to show positive effects. Arjo AB (FRA:A39) maintains a strong order book, indicating a promising outlook for the second half of 2025. Global sales were held back due to difficult comparisons with the previous year, particularly in the UK, which experienced weaker-than-expected sales. Gross margin slightly decreased to 43.4% from 43.6% last year, impacted by currency and US tariff headwinds. Adjusted EBITDA decreased to SEK475 million from SEK496 million in Q2 2024, primarily due to currency and US tariff headwinds. Operating cash flow was SEK205 million, down from SEK344 million in Q2 2024, due to a buildup in working capital and lower EBIT. The company faced a temporary cash flow impact of SEK50 million due to a VAT settlement, affecting cash conversion rates. Q: Can you discuss the potential for further cost reductions for the remainder of the year and the possibility of keeping operating costs flat? A: We will continue our efforts to manage operating expenses. The organic OpEx increase year-over-year in Q2 was 2.1%, which is slightly better than expected. We aim to keep OpEx to sales flat for the full year. Q: Could you quantify the strong order growth and backlog mentioned? A: While we don't report specific figures, the order growth is significantly stronger than last year, and we emphasize this in our communication. Q: What caused the weaker UK sales, and do you expect improvement in the second half? A: UK sales were weaker due to delays in larger orders, likely due to NHS reorganization. We expect these orders to be fulfilled in Q3, which should improve the situation. Q: Are there any tariffs on shipments to the US from Canada and the Dominican Republic? A: Canada is exempt from tariffs, but we pay a 10% base tariff on shipments from the Dominican Republic. We hope the free trade zone might exempt us in the future. Q: Can you provide insights into the gross margin outlook based on the current backlog? A: We are pleased with the order book, particularly in patient handling, but cannot provide specific guidance on gross margin development for the second half. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
